All Eyes Are on IL-15 in Early Phase Studies
A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.
Source: onclive.com
Page 2 - Phasei Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Program Today - Breaking & Trending Today
Treadwell Announces the Formation and Members of Scientific Advisory Board
TORONTO & SAN FRANCISCO, February 14, 2024--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the company’s pipeline of small molecules, biologics and cell therapies.
Source: yahoo.com
Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer
Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.
Source: onclive.com
Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer
Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress
Source: onclive.com
Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC
Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.
Source: onclive.com